CN101703652A - Mastic rheumatism aerosol and preparation method thereof - Google Patents
Mastic rheumatism aerosol and preparation method thereof Download PDFInfo
- Publication number
- CN101703652A CN101703652A CN200910194181A CN200910194181A CN101703652A CN 101703652 A CN101703652 A CN 101703652A CN 200910194181 A CN200910194181 A CN 200910194181A CN 200910194181 A CN200910194181 A CN 200910194181A CN 101703652 A CN101703652 A CN 101703652A
- Authority
- CN
- China
- Prior art keywords
- oleum
- parts
- rheumatism
- mastic
- aerosol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a mastic rheumatism aerosol and a preparation method thereof. The mastic rheumatism aerosol is an aerosol or a spraying agent prepared by taking the raw material medicines of artificial musk, mastic, myrrh, borneol and draconis sanguis as main materials, adding the auxiliary materials of cinnamon oil, peppermint oil, eugenol type basil oil, methyl salicylate, laurocapram, eucalyptus oil, liquid paraffin, essence, a propellant and the like, extracting and preparing; the product has the effects of dispelling rheumatism, promoting blood circulation, relieving pain, decreasing swelling and the like; and the experiments of a plurality of clinical research organizations show that the mastic rheumatism aerosol has obvious curative effect to rheumatalgia, the pain of bones and muscles, the ache of the waist and legs, sciatica and traumatic injuries.
Description
Technical field
The present invention relates to a kind of aerosol or spray, be specifically related to the rare Chinese medicines such as Moschus, Olibanum, Sanguis Draxonis, Myrrha that a kind of employing has effects such as dispelling wind and removing obstruction in the collateral, blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain, novel Chinese patent medicine preparation-mastic rheumatism aerosol that utilization slow release method and aerosol form of medication are made or spray and preparation method thereof.
Background technology
The most frequently used class medicine of treatment of arthritis disease and arthralgia is NSAID (non-steroidal anti-inflammatory drug) (NSAID), and such medicinal application is very extensive; But such medicine has comparatively serious toxic and side effects, studies show that, takes NSAID (non-steroidal anti-inflammatory drug) for a long time and may cause serious consequences such as gastric ulcer, gastrorrhagia and gastric perforation; In addition can also cause the upper digestive tract complication.
At present, treatment rheumatic arthritis remains a kind of difficult miscellaneous diseases that perplex many people; Data show that global rheumatisant has 40,000 ten thousand people approximately, is the hugest in a medical domain disease group; In China, rheumatic arthritis, patient with rheumatoid arthritis account for 18% of population, China's humid area sickness rate up to 40%, 2000 year so far, domestic rheumatisant's medication total amount is above 40,000,000,000 yuan; Hence one can see that, treats rheumatismal medicine and have huge market.And because the difference of administering mode and form of administration causes disease therapeuticing effect difference too big, even delay treatment.
Summary of the invention
The rare Chinese medicines such as Moschus, Olibanum, Sanguis Draxonis, Myrrha that the object of the present invention is to provide a kind of employing to have effects such as dispelling wind and removing obstruction in the collateral, blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain, novel Chinese patent medicine preparation-mastic rheumatism aerosol (containing spray) that utilization Transdermal absorption, slow release method and aerosol or spray form of medication are made and preparation method thereof.
The technical solution adopted in the present invention is:
Employing of the present invention has rare Chinese medicines such as the Moschus, Olibanum, Sanguis Draxonis, Myrrha of effects such as dispelling wind and removing obstruction in the collateral, blood circulation promoting and blood stasis dispelling, promoting the circulation of QI to relieve pain, and novel Chinese patent medicine preparation-mastic rheumatism aerosol that utilization Transdermal absorption, slow release method and aerosol or spray form of medication are made is made by weight proportion by following raw material:
Crude drug is: artificial Moschus 0.2-5 part, Olibanum 10-25 part, Myrrha 10-25 part, Borneolum Syntheticum 2-8 part, Sanguis Draxonis 3-10 part;
Adjuvant is: Oleum Cinnamomi 10-20 part, Oleum menthae 40-50 part, Oleum Ocimi Gratissimi 10-20 part, methyl salicylate 50-100 part, laurocapram 5-10 part, Oleum Eucalypti are an amount of, liquid Paraffin 5-10 part, essence is an amount of, propellant is an amount of.
Production of aerosol is as follows:
(1) get Olibanum 10-25 part, Myrrha 10-25 part, Sanguis Draxonis 3-10 part is ground into coarse powder, is solvent with Oleum Eucalypti, adopts conventional extracting method successively to extract twice, mixed extract filters, and is stand-by;
(2) with artificial Moschus 0.2-5 part pulverization, stand-by; With Borneolum Syntheticum 2-8 part pulverization, stand-by;
(3) the second step gained powder is dissolved in the first step gained filtrate, fully stirs, make it dissolving; Then, it is an amount of to add Oleum Cinnamomi 10-20 part, Oleum menthae 40-50 part, Oleum Ocimi Gratissimi 10-20 part, methyl salicylate 50-100 part, laurocapram 5-10 part, liquid Paraffin 5-10 part, essence successively, makes it mix homogeneously;
(4) add Oleum Eucalypti to ormal weight, filter;
(5) with the filtrate packing, seal, add propellant, pack mastic rheumatism aerosol.
The spray preparation method is as follows:
(1) get Olibanum 10-25 part, Myrrha 10-25 part, Sanguis Draxonis 3-10 part is ground into coarse powder, is solvent with Oleum Eucalypti, adopts conventional extracting method successively to extract twice, mixed extract filters, and is stand-by;
(2) with artificial Moschus 0.2-5 part pulverization, stand-by; With Borneolum Syntheticum 2-8 part pulverization, stand-by;
(3) the second step gained powder is dissolved in the first step gained filtrate, fully stirs, make it dissolving; Then, it is an amount of to add Oleum Cinnamomi 10-20 part, Oleum menthae 40-50 part, Oleum Ocimi Gratissimi 10-20 part, methyl salicylate 50-100 part, laurocapram 5-10 part, liquid Paraffin 5-10 part, essence successively, makes it mix homogeneously;
(4) add Oleum Eucalypti to ormal weight, filter;
(5) with the filtrate packing, seal, pack the mastic rheumatism spray.
Essence described in the present invention comprises musk essence, Oleum Camelliae essence, Fructus Citri Limoniae essence, rose essence, Herba Menthae essence, apple essence etc.
Propellant described in the present invention comprises one or more the mixture in the medicinal propellant that China such as third butane, iso-butane, HFA-134a, HFC-227, dimethyl ether allow to use.
Mastic rheumatism aerosol dosage form of the present invention comprises aerosol and spray.
Mastic rheumatism aerosol of the present invention or spray preparing process are known in those skilled in the art, can carry out according to the preparation method of common spray or aerosol.
The mastic rheumatism aerosol that the present invention relates to (containing spray) is Guangdong Province's famous-brand and high-quality goods of producing in this enterprise--Moschus dispels the wind on the basis of wet oil and Moschus wind-damp dispelling cream, adopts the aerosol and the spray product of a new generation's treatment rheumatism of innovative technologies developments such as slow release, Transdermal absorption; Effects such as this product has wind-damp dispelling, invigorates blood circulation, eases pain, detumescence; Test shows that rheumatalgia, bones and muscles pain, waist and leg ache, sciatica and traumatic injury are all had significant curative effect through how tame clinical research mechanism.
The present invention has the following advantages:
1. by percutaneous drug delivery, can play a role rapidly, and convenient drug administration, good patient compliance.
2. use aerosol or spray dosage form percutaneous drug delivery mode, can avoid gastrointestinal tract, effectively improve the curative effect of bioavailability of medicament, raising medicine, have practical value the decomposition of medicine and the first pass effect of liver.
3. the percutaneous drug delivery mode can avoid medicine to the gastrointestinal stimulation, reduces the toxic and side effects of medicine.
4. dosage form involved in the present invention is the preparation of hermetic type, can prevent effectively that medicine is contaminated, improves medicine stability.
The clinical efficacy test
Mastic rheumatism aerosol or the test of spray clinical efficacy are implemented by Hubei Prov. Inst. of Traditional Chinese Medicine, result of the test shows: two groups of curative effects of treatment group and matched group compare: treatment group clinical recovery 0 example (0%), produce effects 6 examples (16.7%), effective 23 examples (63.9%), invalid 7 examples (19.4%), total effective rate 80.6%.Matched group clinical recovery 0 example (0%), produce effects 5 examples (13.9%), effective 23 examples (63.9%), invalid 8 examples (22.2%), total effective rate 77.8%.Compare P＞0.05, not statistically significant, treatment group and matched group therapeutic equivalence between two groups of groups.The tcm syndrome integration: treating preceding integration for two groups has comparability, treats all to have clear improvement before the back integration is treated.Compare P＞0.05 not statistically significant between two groups of groups, illustrate that two groups of medicines are all effective in cure to the sick tcm syndrome of numbness, and two groups of therapeutic equivalences.Individual event clinical symptoms curative effect, P between two groups of groups＞0.05 not statistically significant illustrates therapeutic equivalence.Experimental result such as following table:
Efficacy analysis (1) between table 1 liang group
Efficacy analysis (2) between table 2 liang group
Table 3 treatment back tcm symptom total mark
Table 4 is examined back tcm syndrome total mark minimizing value
Table 5 treatment back tcm symptom total mark slip relatively
Table 6 treatment back tcm symptom is kept the score
Pairing rank test in the group before and after table 7 tcm symptom is kept the score and treated
Table 8 treatment back tcm symptom disappearance rate (%)
Table 9 treatment back tcm symptom is kept the score and is subtracted score value
Table 10 is controlled between the ESR group of back and is compared
The clinical safety test
The test of mastic rheumatism aerosol clinical safety is implemented experimental study by Hubei Prov. Inst. of Traditional Chinese Medicine, and result of study shows: treatment group and matched group heart rate, blood pressure before and after the medication, medication does not all have big variation.Adverse events, treatment are organized 3 examples (8.3%), matched group 6 examples (12.5%).All relevant with medicine is untoward reaction, and it is main all showing as medication place skin itching, and erythra appears in minority, is slightly, suspends or the replacing agents area, and erythra can disappear, and does not all influence the test process, and above-mentioned untoward reaction may be relevant with patient's allergic constitution.Patient's lab index is normally in the entire test, abnormal conditions do not occur.Experimental result such as following table:
A situation arises for table 11 adverse events
* the definite probabilistic method check of Fisher ' s
The relation of table 12 adverse events and trial drug
* the definite probabilistic method check of Fisher ' s
Annotate: because adverse events all " is affirmed relevant " with trial drug, so the adverse events incidence rate is adverse reaction rate
Table 13 untoward reaction occurrence type and example are inferior
Table 14 adverse events inventory
Table 15 treatment back---lab testing
Table 16 treatment back---the lab testing result judges formation (%)
Annotate: treatment back routine urinalysis, Electrocardioscopy 72 examples are " normally "
Lab testing changes before and after table 17 treatment
The specific embodiment
Below set forth the present invention by instantiation, it should be understood that these embodiment only are used to illustrate the present invention, do not limit the scope of the invention.
Embodiment 1
Crude drug is: 0.2 part of artificial Moschus, 10 parts of Olibanums, 10 parts of Myrrhas, 2 parts of Borneolum Syntheticums, 3 parts of Sanguis Draxonis;
Adjuvant is: 10 parts of Oleum Cinnamomi, 40 parts of Oleum menthaes, 10 parts of Oleum Ocimi Gratissimis, 50 parts of methyl salicylate, 5 parts of laurocaprams, Oleum Eucalypti are an amount of, 5 parts of liquid Paraffin, musk essence is an amount of, propellant is an amount of.
Preparation method is as follows:
(1) get 10 parts of Olibanums, 1 part of Myrrha, Sanguis Draxonis is ground into coarse powder for 3 parts, is that solvent successively extracts twice with conventional extracting method with Oleum Eucalypti, mixed extract filters, and is stand-by;
(2) with 0.2 part of pulverization of artificial Moschus, stand-by; With 2 parts of pulverizations of Borneolum Syntheticum, stand-by;
(3) the second step gained powder is dissolved in the first step gained filtrate, fully stirs, make it dissolving; Then, it is an amount of to add 10 parts of Oleum Cinnamomi, 40 parts of Oleum menthaes, 10 parts of Oleum Ocimi Gratissimis, 50 parts of methyl salicylate, 5 parts of laurocaprams, 5 parts of liquid Paraffin, musk essence successively, makes it mix homogeneously;
(4) add Oleum Eucalypti to ormal weight, filter;
(5) with the filtrate packing, seal, add propellant, pack mastic rheumatism aerosol.
Embodiment 2
Crude drug is: 0.8 part of artificial Moschus, 15 parts of Olibanums, 15 parts of Myrrhas, 6 parts of Borneolum Syntheticums, 5 parts of Sanguis Draxonis;
Adjuvant is: 20 parts of Oleum Cinnamomi, 40 parts of Oleum menthaes, 12 parts of Oleum Ocimi Gratissimis, 70 parts of methyl salicylate, 6 parts of laurocaprams, 100 parts of Oleum Eucalyptis, 10 parts of liquid Paraffin, Oleum Camelliae essence is an amount of, propellant is an amount of.
Preparation method is as follows:
(1) get 15 parts of Olibanums, 15 parts of Myrrhas, Sanguis Draxonis is ground into coarse powder for 5 parts, is that solvent successively extracts twice with Oleum Eucalypti, mixed extract filters, and is stand-by;
(2) with 0.8 part of pulverization of artificial Moschus, stand-by; With 6 parts of pulverizations of Borneolum Syntheticum, stand-by;
(3) the second step gained powder is dissolved in the first step gained filtrate, fully stirs, make it dissolving; Then, it is an amount of to add 20 parts of Oleum Cinnamomi, 40 parts of Oleum menthaes, 12 parts of Oleum Ocimi Gratissimis, 70 parts of methyl salicylate, 6 parts of laurocaprams, 10 parts of liquid Paraffin, Oleum Camelliae essence successively, makes it mix homogeneously;
(4) add Oleum Eucalypti to ormal weight, filter;
(5) with the filtrate packing, seal, add propellant, pack the mastic rheumatism spray.
Embodiment 3
Crude drug is: 1.1 parts of artificial Moschuss, 15 parts of Olibanums, 20 parts of Myrrhas, 8 parts of Borneolum Syntheticums, 10 parts of Sanguis Draxonis;
Adjuvant is: 15 parts of Oleum Cinnamomi, 50 parts of Oleum menthaes, 20 parts of Oleum Ocimi Gratissimis, 80 parts of methyl salicylate, 10 parts of laurocaprams, 150 parts of Oleum Eucalyptis, 8 parts of liquid Paraffin, Fructus Citri Limoniae essence is an amount of, propellant is an amount of.
Preparation method is as follows:
(1) get 15 parts of Olibanums, 20 parts of Myrrhas, Sanguis Draxonis is ground into coarse powder for 10 parts, is that solvent successively extracts twice with Oleum Eucalypti, mixed extract filters, and is stand-by;
(2) with 1.1 parts of pulverizations of artificial Moschus, stand-by; With 8 parts of pulverizations of Borneolum Syntheticum, stand-by;
(3) the second step gained powder is dissolved in the first step gained filtrate, fully stirs, make it dissolving; Then, it is an amount of to add 15 parts of Oleum Cinnamomi, 50 parts of Oleum menthaes, 20 parts of Oleum Ocimi Gratissimis, 80 parts of methyl salicylate, 10 parts of laurocaprams, 8 parts of liquid Paraffin, Fructus Citri Limoniae essence successively, makes it mix homogeneously.
(4) add Oleum Eucalypti to ormal weight, filter;
(5) with the filtrate packing, seal, add propellant, pack mastic rheumatism aerosol.
Embodiment 4
Crude drug is: 1.5 parts of artificial Moschuss, 25 parts of Olibanums, 10 parts of Myrrhas, 4 parts of Borneolum Syntheticums, 8 parts of Sanguis Draxonis;
Adjuvant is: 17 parts of Oleum Cinnamomi, 50 parts of Oleum menthaes, 20 parts of Oleum Ocimi Gratissimis, 100 parts of methyl salicylate, 5 parts of laurocaprams, 200 parts of Oleum Eucalyptis, 10 parts of liquid Paraffin, rose essence is an amount of, propellant is an amount of.
Preparation method is as follows:
(1) get 25 parts of Olibanums, 10 parts of Myrrhas, Sanguis Draxonis is ground into coarse powder for 8 parts, is that solvent successively extracts twice with Oleum Eucalypti, mixed extract filters, and is stand-by;
(2) with 1.5 parts of pulverizations of artificial Moschus, stand-by; With 4 parts of pulverizations of Borneolum Syntheticum, stand-by;
(3) the second step gained powder is dissolved in the first step gained filtrate, fully stirs, make it dissolving; Then, it is an amount of to add 17 parts of Oleum Cinnamomi, 50 parts of Oleum menthaes, 20 parts of Oleum Ocimi Gratissimis, 100 parts of methyl salicylate, 5 parts of laurocaprams, 10 parts of liquid Paraffin, rose essence successively.
(4) add Oleum Eucalypti to ormal weight, filter;
(5) with the filtrate packing, seal, add propellant, pack mastic rheumatism aerosol.
Embodiment 5
Crude drug is: 2.0 parts of artificial Moschuss, 25 parts of Olibanums, 25 parts of Myrrhas, 8 parts of Borneolum Syntheticums, 10 parts of Sanguis Draxonis;
Adjuvant is: 20 parts of Oleum Cinnamomi, 50 parts of Oleum menthaes, 20 parts of Oleum Ocimi Gratissimis, 100 parts of methyl salicylate, 10 parts of laurocaprams, 200 parts of Oleum Eucalyptis, 10 parts of liquid Paraffin, Herba Menthae essence is an amount of, propellant is an amount of.
Preparation method is as follows:
(1) get 25 parts of Olibanums, 25 parts of Myrrhas, Sanguis Draxonis is ground into coarse powder for 10 parts, is that solvent successively extracts twice with Oleum Eucalypti, mixed extract filters, and is stand-by;
(2) with 2.0 parts of pulverizations of artificial Moschus, stand-by; With 8 parts of pulverizations of Borneolum Syntheticum, stand-by;
(3) the second step gained powder is dissolved in the first step gained filtrate, fully stirs, make it dissolving; Then, it is an amount of to add 20 parts of Oleum Cinnamomi, 50 parts of Oleum menthaes, 20 parts of Oleum Ocimi Gratissimis, 100 parts of methyl salicylate, 10 parts of laurocaprams, 10 parts of liquid Paraffin, Herba Menthae essence successively, makes it mix homogeneously.
(4) add Oleum Eucalypti to ormal weight, filter;
(5) with the filtrate packing, seal, add propellant, pack mastic rheumatism aerosol.
Embodiment 6
Crude drug is: 2.2 parts of artificial Moschuss, 15 parts of Olibanums, 15 parts of Myrrhas, 6 parts of Borneolum Syntheticums, 5 parts of Sanguis Draxonis;
Adjuvant is: 20 parts of Oleum Cinnamomi, 40 parts of Oleum menthaes, 12 parts of Oleum Ocimi Gratissimis, 70 parts of methyl salicylate, 6 parts of laurocaprams, 100 parts of Oleum Eucalyptis, 10 parts of liquid Paraffin, apple essence is an amount of, propellant is an amount of.
Preparation method is as follows:
(1) get 15 parts of Olibanums, 15 parts of Myrrhas, Sanguis Draxonis is ground into coarse powder for 5 parts, is that solvent successively extracts twice with Oleum Eucalypti, mixed extract filters, and is stand-by;
(2) with 2.2 parts of pulverizations of artificial Moschus, stand-by; With 6 parts of pulverizations of Borneolum Syntheticum, stand-by;
(3) the second step gained powder is dissolved in the first step gained filtrate, fully stirs, make it dissolving; Then, it is an amount of to add 20 parts of Oleum Cinnamomi, 40 parts of Oleum menthaes, 12 parts of Oleum Ocimi Gratissimis, 70 parts of methyl salicylate, 6 parts of laurocaprams, 10 parts of liquid Paraffin, apple essence successively, makes it mix homogeneously;
(4) add Oleum Eucalypti to ormal weight, filter;
(5) with the filtrate packing, seal, pack the mastic rheumatism spray.
Embodiment 7
Crude drug is: 3.0 parts of artificial Moschuss, 25 parts of Olibanums, 10 parts of Myrrhas, 4 parts of Borneolum Syntheticums, 8 parts of Sanguis Draxonis;
Adjuvant is: 17 parts of Oleum Cinnamomi, 50 parts of Oleum menthaes, 20 parts of Oleum Ocimi Gratissimis, 100 parts of methyl salicylate, 5 parts of laurocaprams, 200 parts of Oleum Eucalyptis, 10 parts of liquid Paraffin, Fructus Citri Limoniae essence is an amount of, propellant is an amount of.
Preparation method is as follows:
(1) get 25 parts of Olibanums, 10 parts of Myrrhas, Sanguis Draxonis is ground into coarse powder for 8 parts, is that solvent successively extracts twice with Oleum Eucalypti, mixed extract filters, and is stand-by;
(2) with 3.0 parts of pulverizations of artificial Moschus, stand-by; With 4 parts of pulverizations of Borneolum Syntheticum, stand-by;
(3) the second step gained powder is dissolved in the first step gained filtrate, fully stirs, make it dissolving; Then, it is an amount of to add 17 parts of Oleum Cinnamomi, 50 parts of Oleum menthaes, 20 parts of Oleum Ocimi Gratissimis, 100 parts of methyl salicylate, 5 parts of laurocaprams, 10 parts of liquid Paraffin, Fructus Citri Limoniae essence successively.
(4) add Oleum Eucalypti to ormal weight, filter;
(5) with the filtrate packing, seal, pack the mastic rheumatism spray.
Claims (7)
1. mastic rheumatism aerosol is characterized in that: made by weight proportion by following raw material:
Crude drug is: artificial Moschus 0.2-5 part, Olibanum 10-25 part, Myrrha 10-25 part, Borneolum Syntheticum 2-8 part, Sanguis Draxonis 3-10 part;
Adjuvant is: Oleum Cinnamomi 10-20 part, Oleum menthae 40-50 part, Oleum Ocimi Gratissimi 10-20 part, methyl salicylate 50-100 part, laurocapram 5-10 part, Oleum Eucalypti are an amount of, liquid Paraffin 5-10 part, essence is an amount of, propellant is an amount of.
2. a method that is used to prepare the described mastic rheumatism aerosol of claim 1 is characterized in that: comprise the steps:
(1) get Olibanum 10-25 part, Myrrha 10-25 part, Sanguis Draxonis 3-10 part is ground into coarse powder, is solvent with Oleum Eucalypti, successively extracts twice with conventional extracting method, mixed extract filters, and is stand-by;
(2) with artificial Moschus 0.2-5 part pulverization, stand-by; With Borneolum Syntheticum 2-8 part pulverization, stand-by;
(3) step (2) gained powder is dissolved in step (1) the gained filtrate, fully stirs, make it dissolving; Then, it is an amount of to add Oleum Cinnamomi 10-20 part, Oleum menthae 40-50 part, Oleum Ocimi Gratissimi 10-20 part, methyl salicylate 50-100 part, laurocapram 5-10 part, liquid Paraffin 5-10 part, essence successively, makes it mix homogeneously;
(4) add Oleum Eucalypti to ormal weight, filter;
(5) with the filtrate packing, seal, add propellant, pack mastic rheumatism aerosol.
3. mastic rheumatism spray is characterized in that: made by weight proportion by following raw material:
Crude drug is: artificial Moschus 0.2-5 part, Olibanum 10-25 part, Myrrha 10-25 part, Borneolum Syntheticum 2-8 part, Sanguis Draxonis 3-10 part;
Adjuvant is: Oleum Cinnamomi 10-20 part, Oleum menthae 40-50 part, Oleum Ocimi Gratissimi 10-20 part, methyl salicylate 50-100 part, laurocapram 5-10 part, Oleum Eucalypti are an amount of, liquid Paraffin 5-10 part, essence are an amount of.
4. a method that is used to prepare the described mastic rheumatism spray of claim 3 is characterized in that: comprise the steps:
(1) get Olibanum 10-25 part, Myrrha 10-25 part, Sanguis Draxonis 3-10 part is ground into coarse powder, is solvent with Oleum Eucalypti, successively extracts twice with conventional extracting method, mixed extract filters, and is stand-by;
(2) with artificial Moschus 0.2-5 part pulverization, stand-by; With Borneolum Syntheticum 2-8 part pulverization, stand-by;
(3) step (2) gained powder is dissolved in step (1) the gained filtrate, fully stirs, make it dissolving; Then, it is an amount of to add Oleum Cinnamomi 10-20 part, Oleum menthae 40-50 part, Oleum Ocimi Gratissimi 10-20 part, methyl salicylate 50-100 part, laurocapram 5-10 part, liquid Paraffin 5-10 part, essence successively, makes it mix homogeneously;
(4) add Oleum Eucalypti to ormal weight, filter;
(5) with the filtrate packing, seal, pack the mastic rheumatism spray.
5. according to any described a kind of mastic rheumatism aerosol of claim 1-4 or spray, it is characterized in that described essence comprises musk essence, Oleum Camelliae essence, Fructus Citri Limoniae essence, rose essence, Herba Menthae essence, apple essence.
6. according to any described a kind of mastic rheumatism aerosol of claim 1-4 or spray, it is characterized in that described propellant is one or more the mixture in China medicinal propellant third butane, iso-butane, tetrafluoroethane HFA-134a, heptafluoro-propane HFC-227 or the dimethyl ether that allow to use.
7. be known in those skilled in the art according to claim 2 or 4 described mastic rheumatism aerosols or spray preparing process, prepare according to the preparation method of common spray or aerosol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910194181A CN101703652A (en) | 2009-11-26 | 2009-11-26 | Mastic rheumatism aerosol and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910194181A CN101703652A (en) | 2009-11-26 | 2009-11-26 | Mastic rheumatism aerosol and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101703652A true CN101703652A (en) | 2010-05-12 |
Family
ID=42373949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910194181A Pending CN101703652A (en) | 2009-11-26 | 2009-11-26 | Mastic rheumatism aerosol and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101703652A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102872288A (en) * | 2012-11-05 | 2013-01-16 | 广东同德药业有限公司 | Frankincense rheumatism aerosol for curing rheumatism bone ache and preparation method thereof |
| CN103083393A (en) * | 2013-01-24 | 2013-05-08 | 山西华诚睿光生物科技有限公司 | Disinfect and sterile spray for preventing bouine mastitis and preparation method of spray |
| CN103356864A (en) * | 2012-04-04 | 2013-10-23 | 吴舒克 | Aerosol spray for treating cervical spondylosis |
| CN103356850A (en) * | 2012-04-04 | 2013-10-23 | 吴舒克 | Aerosol spray for treating cervical spondylosis |
| CN103356834A (en) * | 2012-04-04 | 2013-10-23 | 吴舒克 | Jingtongling aerosol spray |
| CN105708945A (en) * | 2016-02-03 | 2016-06-29 | 扬州大学 | Traditional Chinese medicine aerosol composition for external use |
| CN109260406A (en) * | 2018-12-04 | 2019-01-25 | 王兴峰 | A kind of traditional Chinese medicinal ointment for treating rheumatism and pain of straining |
| CN110302347A (en) * | 2019-07-22 | 2019-10-08 | 李健康 | A kind of analgesic tincture and preparation method thereof for treating wound rheumatism |
| CN112891457A (en) * | 2019-11-19 | 2021-06-04 | 马学周 | Quick bone-setting plaster for treating bone fracture, preparation method and use method |
| CN112915145A (en) * | 2021-01-28 | 2021-06-08 | 孙玉宝 | Purple sand cupping glass and preparation method and application thereof |
| CN113144044A (en) * | 2021-04-16 | 2021-07-23 | 巩振尧 | Anti-infection skin and bone regeneration medicine composition for injury |
| CN113876908A (en) * | 2021-10-29 | 2022-01-04 | 谢庆祥 | Pain-relieving and scald-treating medicinal liquor and preparation method thereof |
-
2009
- 2009-11-26 CN CN200910194181A patent/CN101703652A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103356864A (en) * | 2012-04-04 | 2013-10-23 | 吴舒克 | Aerosol spray for treating cervical spondylosis |
| CN103356850A (en) * | 2012-04-04 | 2013-10-23 | 吴舒克 | Aerosol spray for treating cervical spondylosis |
| CN103356834A (en) * | 2012-04-04 | 2013-10-23 | 吴舒克 | Jingtongling aerosol spray |
| CN102872288B (en) * | 2012-11-05 | 2014-10-22 | 广东同德药业有限公司 | Frankincense rheumatism aerosol for curing rheumatism bone ache and preparation method thereof |
| CN102872288A (en) * | 2012-11-05 | 2013-01-16 | 广东同德药业有限公司 | Frankincense rheumatism aerosol for curing rheumatism bone ache and preparation method thereof |
| CN103083393B (en) * | 2013-01-24 | 2015-10-28 | 山西华诚睿光生物科技有限公司 | For disinfection spray preventing mammitis of cow and preparation method thereof |
| CN103083393A (en) * | 2013-01-24 | 2013-05-08 | 山西华诚睿光生物科技有限公司 | Disinfect and sterile spray for preventing bouine mastitis and preparation method of spray |
| CN105708945A (en) * | 2016-02-03 | 2016-06-29 | 扬州大学 | Traditional Chinese medicine aerosol composition for external use |
| CN109260406A (en) * | 2018-12-04 | 2019-01-25 | 王兴峰 | A kind of traditional Chinese medicinal ointment for treating rheumatism and pain of straining |
| CN110302347A (en) * | 2019-07-22 | 2019-10-08 | 李健康 | A kind of analgesic tincture and preparation method thereof for treating wound rheumatism |
| CN112891457A (en) * | 2019-11-19 | 2021-06-04 | 马学周 | Quick bone-setting plaster for treating bone fracture, preparation method and use method |
| CN112915145A (en) * | 2021-01-28 | 2021-06-08 | 孙玉宝 | Purple sand cupping glass and preparation method and application thereof |
| CN113144044A (en) * | 2021-04-16 | 2021-07-23 | 巩振尧 | Anti-infection skin and bone regeneration medicine composition for injury |
| CN113876908A (en) * | 2021-10-29 | 2022-01-04 | 谢庆祥 | Pain-relieving and scald-treating medicinal liquor and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101703652A (en) | Mastic rheumatism aerosol and preparation method thereof | |
| CN101933991B (en) | Analgesic and anti-inflammatory medicament and preparation method thereof | |
| CN102743402B (en) | Application of panaxadiol saponins fraction in preparing medicine for preventing dermatitis and scar | |
| WO2005110431A1 (en) | Herbal product containing glucosamine | |
| CN101062022B (en) | Colchicine patch absorbing from skin for treating acute goute arthritis and the preparing method thereof | |
| CN102319294B (en) | Double-vanilla preparation and preparation method thereof | |
| CN101700300A (en) | Traditional Chinese medicine volatile oil composition for treating gastrointestinal dysfunction or irritable bowel syndrome (IBS), and preparation method and applications thereof in preparation of medicaments | |
| CN101327286B (en) | Pain-relieving anti-inflammation medicament and preparation method thereof and use | |
| CN102940751B (en) | A kind of promoting blood circulation and traumatic injury drop pill and preparation method thereof | |
| CN102228547B (en) | Application of traditional Chinese medicine composition in preparing medicaments treating pancreatitis and/or cholecystitis | |
| CN101744873A (en) | Externally used liquid preparation containing only iridoid glycoside and application thereof | |
| CN102670740B (en) | Drug composition for treating soft tissue injuries and preparation process thereof | |
| CN102670624B (en) | Patch for treating rheumatic arthritis and preparation method thereof | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN105362382A (en) | Traditional Chinese medicine composition for treating recurrent oral ulcer and application thereof | |
| CN103638336A (en) | Full rhizoma gastrodiae tablet | |
| CN102512557B (en) | Traditional Chinese medicine for mid-late period recovery from trauma | |
| CN103585330B (en) | A kind of Chinese medicine composition for cutaneous fungal infection and preparation method thereof | |
| CN101468055A (en) | Gel patch for preventing and treating cerebral thrombosis and preparation method thereof | |
| CN108853246B (en) | Anti-inflammatory analgesic traditional Chinese medicine composition and preparation method and application thereof | |
| CN1449800A (en) | Traditional Chinese medicine for treating wind-cold type of common cold and preparation process thereof | |
| CN109806321B (en) | A Chinese medicinal composition, its preparation method and application in preparing medicine for treating trauma | |
| CN101874877A (en) | Medicine combination for promoting blood circulation and removing blood stasis and preparation method thereof | |
| CN100496600C (en) | Medicine for treating osteoporosis and its preparation method | |
| CN105641201A (en) | Pharmaceutical composition for local anaesthesia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20100512 |